9.USES OF KISSPEPTIN AGONISTS AS AN OVULATION TRIGGER FOR THE PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME (Literature Review, 2020–2025)

USES OF KISSPEPTIN AGONISTS AS AN OVULATION TRIGGER FOR THE
PREVENTION OF OVARIAN HYPERSTIMULATION SYNDROME (Literature Review, 2020–2025)

Sharapidinova Aida Maskhoridinovna
Asian International University named after S. Tentishev
Kant, Kyrgyzstan

Abstract

Research objective: to analyze current literature data on the efficacy of using kisspeptin
agonists as an ovulation trigger for the prevention of ovarian hyperstimulation syndrome in high-
risk patients.
Research methods: An analytical review of the scientific literature from 2020 to 2025 was
conducted using the PubMed, Scopus, Embase, Web of Science, and Clinical Trials.gov databases,
as well as the recommendations of the ASRM and ESHRE. The review included randomized clinical
trials, systematic reviews, and meta-analyses focusing on the use of kisspeptin as a trigger in IVF
programs.
Key findings: It was established that the use of kisspeptin agonists ensures effective oocyte
maturation and comparable rates of fertilization and pregnancy, with a significant reduction in the
risk of severe ovarian hyperstimulation syndrome. The most pronounced positive effect was
observed in patients with high ovarian reserve and polycystic ovary syndrome. Additionally, a
reduction in the frequency of embryo transfer cancellations and improved safety of assisted
reproductive technology programs were identified.
Conclusions and clinical implications: The use of a kisspeptin trigger is a promising and
safe method for inducing ovulation, helping to reduce the incidence of complications in assisted
reproductive technology programs and enhance the effectiveness of personalized approaches in
reproductive medicine.

Keywords: OHSS, kisspeptin, IVF, anti-Müllerian hormone, high risk